CVS Health Corporation (CVS)
How CVS' Pharmacy & Consumer Wellness Is Positioned for H2 2026
CVS Health carries strong pharmacy momentum into H2 2026, with rising prescription volume, Rite Aid gains and higher profit.
CVS Health: Discounted, Vertically Integrated Healthcare Winner - Richer Returns Ahead
The vertically integrated healthcare model across insurance, PBM, pharmacy, and clinical care capabilities underscores CVS Health's multi-year margin recovery prospects. This strategy has driven the better patient outcomes, superior membership retention, moderating medical benefit ratios, and robust revenue/margin expansion. Recent selloff has unlocked a cheaper P/E of 11.78x, along with the dual return prospects across capital appreciation to my LTPT of $129.90 and dividend yield of 2.84%.
Is CVS Stock a Buy as Earnings Improve but Key Risks Remain Elevated?
CVS Health enters the second half of 2026 with stronger earnings and Aetna gains, but medical costs and Caremark risks cloud the recovery.
CVS' Q2 EPS Gains From Improved Health Care Benefits Profitability
CVS Health's Q2 EPS jumps more than 40% as Health Care Benefits profitability improves, prompting a major boost to its 2026 AOI outlook.
Can CVS Sustain Its 2026 Recovery After Raising Earnings Guidance?
CVS Health is rebuilding momentum as Aetna drives stronger profits and higher 2026 guidance, but medical costs and PBM changes could test the recovery.
How CVS Is Building on Its Consumer-Health Care Technology Push
CVS Health advances its $20 billion technology push with AI tools, Health100 and automation aimed at simplifying care and improving engagement.
Here's Why CVS Health (CVS) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CVS Health: I Wanted A Beat And Raise, I Got It, And I'm Still At 'Hold'
CVS Health Corporation's strong Q2 results delivered revenue and earnings beats while management raised operating cash flow guidance to $11.5 billion. Aetna turnaround and improved medical benefit ratios boosted first half cash generation, helping drive recent stock gains. Management anticipates higher second half medical costs alongside 2027 headwinds from 340B pricing and pharmacy drug mix shifts.
Broad Market Momentum & Defensive Pivots: This Week's Top ETF Flows
The ETF market saw a massive surge into core index heavyweights this past week, as investors poured billions into broad U.S. equities and mega-cap tech leadership. However, this aggressive accumulation was paired with deliberate defensive positioning in ultra-short Treasuries, spot gold, and healthcare sector exposure.
CVS Health Q2 Earnings Call Highlights
CVS Health NYSE: CVS reported second-quarter results that exceeded its expectations, citing earnings growth across all operating segments and raising its full-year outlook for adjusted earnings per share and operating cash flow.
CVS Health Q2 Earnings and Revenues Top Estimates, Stock Climbs
CVS beats Q2 earnings and revenue estimates as stronger segment performance lifts results and prompts raised 2026 guidance, sending shares higher.
CVS Health tops second-quarter estimates, raises full-year profit outlook
CVS Health Corp (NYSE:CVS) reported second-quarter revenue and profit that beat Wall Street estimates on Wednesday, and raised its full-year adjusted earnings guidance, though cautious guidance pressured shares. Revenue rose 7.3% year-over-year to $106.1 billion, above analyst estimates of $100.11 billion.
